November 22, 2013 / 1:50 PM / in 4 years

EU agency backs new drugs from GSK, Gilead, Otsuka

LONDON, Nov 22 (Reuters) - European regulators said on Friday they had recommended approval of a new drug for HIV from GlaxoSmithKline and a novel hepatitis C treatment from Gilead Sciences.

The European Medicine Agency (EMA) also gave a green light to an Otsuka tuberculosis drug, following a review of an earlier rejection.

Recommendations for marketing approval by the EMA’s Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below